Stelara and Diet Trial for Crohn"s Disease

Crohn Disease Clinical Trial

Official title:

Stelara and CDED Diet Trial for Crohn"s Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04779762
• Other study ID #: STEDI
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2022
• Est. completion date: January 2026

Study information

• Verified date: February 2021
• Source: Wolfson Medical Center
• Contact: Michal Yaakov, Ph.D
• Phone: 972-35028878
• Email: michal.yaakov[@]walla.co.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dietary therapy involving the Crohn's disease exclusion diet (CDED) is an evolving strategy to target the microbiome and innate immunity in order to reduce inflammation and promote healing.

The goal of the current pilot study is to evaluate the added benefit of treatment with Ustekinumab combined with CDED in anti TNF exposed patients compared to treatment with Ustekinumab alone in term of achieving remission.

Description:

The induction period is crucial for a patient's response to biologic therapy but also for maintenance of remission, as simple as it sounds, maintenance of remission requires remission. Biological medications using a single monoclonal antibody directed target, seem to be effective only for a segment of the population with Crohn's disease Dietary therapy is highly effective in children and induces remission in approximately 60% of young adults with uncomplicated luminal disease. It was shown to shift the microbiome away from Proteobacteria towards Firmicutes, and to decrease intestinal permeability (i.e improvement in leaky gut).

Dietary therapy is widely used in children and both exclusive enteral nutrition (EEN) and the Crohn's disease exclusion diet were highly effective for induction of remission and reduction in inflammation in children in a multinational randomized controlled trial (Levine A, Gastroenterology 2019). Recently a prospective randomized controlled trial in biologic naïve adults demonstrated clinical remission in 62% of adults by 6 weeks (Yanai H, UEG Week 2020). A two week course of EEN in adults was effective for improvement of symptoms and reduction in inflammation (Wall CL Inflamm Intest Dis 2018). Xu et al demonstrated clinical remission in 52 and 47% of two adult cohorts (n=104) using EEN for induction of remission (Xu Y, Therap Adv Gastroenterol 2019). Taken together, these studies suggest that dietary therapy could act as a bridge to biologic effect and have a synergistic effect on the disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: January 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Informed consent.

2. Age: 18- 65 years (inclusive).

3. Established diagnosis of CD

4. Starting Ustekinumab.

5. Active disease defined as a CDAI >220, and have an objective measure of disease activity such as an elevated marker of inflammation (elevated CRP >5mg/L or 0.5 mg/dL or calprotectin >150 mcg/g).

6. Patients must have previously received at least one dose of anti TNF at any time in the past.

7. Stable medication at least 8 weeks.

Inclusion criteria comments

1. Patients of any weight will be recruited and randomized to the study regardless of their BMI.

Exclusion Criteria:

1. Pregnancy or lactation

2. Presence of malignancy

3. Use of prednisone >20 mg /day

4. Ongoing use of concurrent medications with a dose change in the previous 8 weeks with the exception of steroids (Patients receiving prednisone 20 mg or less may be enrolled by must be tapered by week 6).

5. Treatment with an anti TNF in the last 4 weeks.

6. Patients who will take oral iron oral supplements during the trial (see comment 1 below).

7. Active infections, tuberculosis, positive stool test for Clostridium difficile toxin.

8. Active perianal fistula (with discharge, or with an abscess during the past 3 months), rectovaginal fistula.

9. Fever.

10. Active extra intestinal disease (arthritis with joint swelling, concurrent liver disease). Patients with skin manifestations and arthralgia may be included.

11. Smokers who smoke >5 more cigarettes a day (see comment 2 below).

12. Renal failure.

13. Uncontrolled diabetes that precludes the diet.

14. Patients with isolated colonic disease distal to the transverse colon (see comment 3 below).

Exclusion criteria comments

1. Patients taking oral iron supplements may be enrolled if they discontinue the supplements prior to receiving UST, and are NOT ALLOWED to take oral iron supplements during the first 12 weeks of the trial as the diet reduces oral iron exposure to decrease siderophoric pathobionts (patients are allowed to receive intravenous iron or other oral vitamins during the trial).

2. Patients who smoke >5 cigarettes per day may be enrolled if they stop smoking from the start of the trial (smoking negates the effect of the diet).

3. Patients with isolated colonic disease distal to the transverse colon and no history of ileal disease will be excluded to make sure that IBDU is not recruited.

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Other:
• Crohn's disease exclusion diet (CDED)
Dietary therapy for Crohn's disease

Drug:
• Ustekinumab Injection [Stelara]
Drug for Crohn's disease

Locations

Country	Name	City	State
Israel	Sheba Medical Center	Ramat Gan

Sponsors (2)

Lead Sponsor	Collaborator
Wolfson Medical Center	Sheba Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ITT, steroid free remission	Defined as an improvement in one inflammatory marker (CRP or calprotectin)	week 12
Secondary	Median calprotectin	Reduction in median calprotectin compared to baseline between groups	week 12
Secondary	Intestinal bowel wall thickness	Reduction in intestinal bowel wall thickness compared to baseline between groups for patients with increased bowel wall thickness measured on baseline US.	week 16
Secondary	UST trough level	mean UST trough level between groups.	week 16
Secondary	CDAI between groups	Median decline in CDAI between groups. Crohn's Disease Activity Index (CDAI) range between 0-800	week 16